Central role of apociii
|
|
- Derek Charles
- 5 years ago
- Views:
Transcription
1 University of Copenhagen & Copenhagen University Hospital Central role of apociii Anne Tybjærg-Hansen MD DMSc Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Denmark ISA Amsterdam
2 Disclosures Anne Tybjærg-Hansen Professor of Clinical Biochemistry and Translational Molecular Cardiology Consultancies and honoraria Eli Lilly and LGC Genomics
3 Agenda apociii History Physiology Genetics suggest reduced risk of ischemic heart disease Genetics suggest a new drug target Genetics suggest target patients
4 History ApoCIII: 46 years old and even more interesting Adapted from Ginsberg and Brown ATVB 2011
5 ApoCIII, a component of VLDL and an inhibitor of lipoprotein lipase
6 ApoCIII, alignment and complete amino acid sequence
7 APOC3 gene
8 ApoCIII inhibits lipoprotein remnant uptake by the liver
9 Studies in mice
10 Physiology
11 Adapted from Gaudet et al. NEJM 2014
12 ApoCIII Ooi E et al. Clin Sci 2008;114:61124.
13 Sacks F et al. Circulation 2000
14 Clinical use Clinical use Alternative HDL HDL cholesterol Apo A1 Triglycerides LDL Remnants LDL cholesterol Remnant or VLDL cholesterol ApoB or non-hdl cholesterol Triglycerides Cholesterol
15 Plasma Intima LDL LDL Remnants Remnants LPL FFA + Monoacylglycerol Inflammation LPL Macrophage Cholesterol Chylomicron Triglycerides Foam cells Nordestgaard & Varbo, Lancet 2014; 384:
16 ApoCIII, direct proatherogenic role? Increased binding to proteoglycans Increases monocyte binding to cultured endothelial cells via stimulation of VCAM-1
17 Genetics suggest reduced risk of ischemic cardiovascular disease
18 Department of Clinical Biochemistry, Rigshospitalet Chromosome 11q23 (metaphase) 5 APOA1 APOA4 25 kilobasepairs APOA5 3 3 APOC3 5
19 Department of Clinical Biochemistry, Rigshospitalet Exon 1 untranslated APOC3 Exon Promoter Exon 2 Exon 4 Pre-protein: 99 amino acids 20 amino acid signal peptide Mature protein: 79 amino acids
20
21 R19X HAPI Study
22 Amish Family Calcification Study
23
24 Anders Berg Jørgensen MD PhD APOC3 No. of participants No. of events Triglycerides Theoretically predicted risk Observed risk P-value Ischemic vascular disease Any mutation Wildtype 75,465 10,770 All heterozygotes P = 2x10-54 P = % - 41% Ischemic heart disease Any mutation Wildtype All heterozygotes 75, , P = 2x10-54 P = Triglycerides (mmol/l) Hazard ratio (95% CI) Hazard ratio (95% CI)
25 Nordestgaard & Varbo, Lancet 2014; 384: APOC3 Jørgensen et al NEJM 2014 APOC3 TG and HDL Working Group NEJM Ischemic vascular disease N alleles N total N events Risk estimate - 44% - 39% Triglycerides, mmol/l 75,465 10, ,472 33, Hazard ratio (95% CI) PCSK9 CGPS & CCHS % 64,492 10,665 1, LDL cholesterol, mmol/l Hazard ratio (95% CI)
26 Plasma Intima LDL LDL Remnants Remnants LPL FFA + Monoacylglycerol Inflammation LPL Macrophage Cholesterol Chylomicron Triglycerides Foam cells Nordestgaard & Varbo, Lancet 2014; 384:
27
28 Mendelian randomization hypotheses established but causal? Biomarker 1 Disease Risk effect size? pleiotropic effects? 2 3 Genotype statistical power?
29 Department of Clinical Biochemistry, Rigshospitalet Jørgensen AB et al. NEJM 2014 APOC3 Any mutation Wildtype No. of participants 75,465 Mean + SE P = 2x10-54 Mean + SE P = 2x10-29 Mean + SE P = 0.06 All heterozygotes % 24% -3% R19X Wildtype 75,692 P = 3x10-9 P = 3x10-5 P = 0.35 Heterozygotes 33-48% 26% 7% IVS2+1G>A Wildtype 75,516 P = 4x10-43 P = 2x10-25 P = 0.01 Heterozygotes % 24% -5% A43T Wildtype 75,707 P = 3x10-5 P = 0.13 P = 0.83 Heterozygotes 18-47% 15% 2% Triglycerides (mmol/l) HDL cholesterol (mmol/l) LDL cholesterol (mmol/l)
30 APOC3 and statin treatment Corrected for statin use N Mean (+SE) (%) P Mean (+SE) (%) P Noncarriers 75,465 All heterozygotes % 5x % Excluding statin users Noncarriers 68,419 All heterozygotes % 2x % Remnant cholesterol LDL cholesterol
31
32 Genetics suggest a new drug target
33 Intermediate phenotype Disease Risk Undesirable effects? Genotype
34 Summary: Loss-of-function variants in APOC3 43% reduction in calculated remnant cholesterol 41% reduction in risk of ischemic heart disease Not explained by reduction in LDL cholesterol Suggests that APOC3 is a relevant drug target
35 Department of Clinical Biochemistry, Rigshospitalet 2013;12: Objective:To test the hypothesis that selective inhibition of apociii with antisense drugs in preclinical models and in healthy volunteers would reduce plasma apociii and triglyceride levels. (human apociii ASO ISIS ).
36 Administration of ISIS to healthy human volunteers produced dose- and time-dependent reductions in apolipoprotein C-III (apoc-iii) and triglycerides levels. Mark J. Graham et al. Circulation Research. 2013;112: Copyright American Heart Association, Inc. All rights reserved.
37 Administration of ISIS to healthy human volunteers produced dose- and timedependent reductions in apolipoprotein C-III (apoc-iii) and triglycerides levels. Graham MJ et al. Circ Res 2013
38 Genetics suggest target patients
39 N Engl J Med Volume 371(23): December 4, 2014 Genetic disorder characterized by severe hypertriglyceridemia and recurrent pancreatitis due to a deficiency in lipoprotein lipase. Lack of efficient therapies except extreme fat restriction or LPL gene replacement.
40 Study overview 3 patients homozygous or compound heterozygous for severe loss-of-function mutations in LPL (triglycerides mmol/l; P207L or G188E) ISIS ASO 300mg once weekly as s.c. injection for 13 weeks
41 Effect of ISIS ASO 300mg once weekly as s.c. injection for 13 weeks Gaudet D et al. N Engl J Med 2014;371:
42 Plasma triglyceride metabolism and the role of apociii. Gaudet D et al. N Engl J Med 2014;371:
43 Summary Inhibition of ApoCIII had a profound and clinically relevant effect on triglyceride levels through a mechanism that is independent of lipoprotein lipase
44 ApoCIII: 46 years old and even more interesting Adapted from Ginsberg and Brown ATVB 2011
45 EAS Innsbruck 2016
46
47 Rare mutations in APOC3 and plasma levels of triglycerides. The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. N Engl J Med 2014;371:22-31
48 Association of four APOC3 mutations with plasma lipid levels in replication studies. The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. N Engl J Med 2014;371:22-31
49 Amish Family Calcification Study
50 National Health and Nutrition Examination Surveys Crawford et al. Circ Cardiovasc Genet 2014
51 NHANES Crawford et al. Circ Cardiovasc Genet 2014
52 TwinsUK and Avon Longitudinal Study of Parents and Children Timpson et al. Nature Commun 2014
53 Can the reduction in risk of CHD in the APOC3 mutant carriers be explained by the reduction in LDL cholesterol levels? Could the contribution of LDL cholesterol be masked by statin treatment?
54 Characteristics of APOC3 heterozygotes
The Role of Apolipoprotein CIII in Coronary Artery Disease. Disclosures
Miami Cardiac & Vascular Institute Cardiovascular Disease Prevention 15th Annual Symposium February 16, 2017 Nobu Eden Roc Hotel, Miami Beach, Florida. The Role of Apolipoprotein CIII in Coronary Artery
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationNature Genetics: doi: /ng.3561
Supplementary Figure 1 Pedigrees of families with APOB p.gln725* mutation and APOB p.gly1829glufs8 mutation (a,b) Pedigrees of families with APOB p.gln725* mutation. (c) Pedigree of family with APOB p.gly1829glufs8
More informationInhibition of PCSK9: The Birth of a New Therapy
Inhibition of PCSK9: The Birth of a New Therapy Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Disclosures Dr. Kastelein
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationZuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
More informationLoss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
The new england journal of medicine original article Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease Anders Berg Jørgensen, M.D., Ph.D., Ruth Frikke-Schmidt, M.D., D.M.Sc., Børge
More informationLoss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
The new england journal of medicine original article Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease Anders Berg Jørgensen, M.D., Ph.D., Ruth Frikke-Schmidt, M.D., D.M.Sc., Børge
More informationLipoproteins Metabolism
Lipoproteins Metabolism LEARNING OBJECTIVES By the end of this Lecture, the student should be able to describe: What are Lipoproteins? Describe Lipoprotein Particles. Composition of Lipoproteins. The chemical
More informationMetabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD
Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy
More informationLipid Metabolism in Familial Hypercholesterolemia
Lipid Metabolism in Familial Hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More informationAntisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes Andres Digenio, MD, PhD; Richard L. Dunbar, MD; Veronica J. Alexander,
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationHypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC
Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More information~550 founders
Lipid GWAS in the Amish: New Insights into Old Genes Coleen M. Damcott, PhD Assistant Professor of Medicine Division of Endocrinology, Diabetes and Nutrition Program in Genetics and Genomic Medicine University
More informationLipid Lowering in Patients at High Risk for Cardiovascular Disease
Lipid Lowering in Patients at High Risk for Cardiovascular Disease Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Novel
More informationHigh density lipoprotein metabolism
High density lipoprotein metabolism Lipoprotein classes and atherosclerosis Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic Plasma lipid transport Liver VLDL FC
More informationATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS
LABORATORY AND RISK FACTORS OF ATHEROSCLEROSIS S R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty RISK FACTORS FOR CHD Clinical Risk Factors Laboratory Risk Factors MAJOR CLINICAL RISK
More informationGenetic and biochemical characteristics of patients with hyperlipidemia who require LDL apheresis
Genetic and biochemical characteristics of patients with hyperlipidemia who require LDL apheresis Mato Nagel, Ioan Duma, Constantina Vlad, Mandy Benke, Sylvia Nagorka Zentrum für Nephrologie & Stoffwechsel,
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationPCSK9 Inhibition: From Genetics to Patients
PCSK9 Inhibition: From Genetics to Patients John Chapman BSc, Ph.D., D.Sc., FESC Research Professor, University of Pierre and Marie Curie Director Emeritus, INSERM Dyslipidemia and Atherosclerosis Research
More information1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
More informationLipid/Lipoprotein Structure and Metabolism (Overview)
Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures
More informationDisclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017
Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital
More informationLipids digestion and absorption, Biochemistry II
Lipids digestion and absorption, blood plasma lipids, lipoproteins Biochemistry II Lecture 1 2008 (J.S.) Triacylglycerols (as well as free fatty acids and both free and esterified cholesterol) are very
More informationCholesterol; what are the future lipid targets?
Cholesterol; what are the future lipid targets? lipidologist out-of-business in 5-10 years? G.Kees Hovingh dept of vascular medicine, Academic Medical Center g.k.hovingh@amc.uva.nl Disclosure - Consultant
More informationThe Addition of Ezetimibe to Statin therapy in. Patients with Homozygous Familial. Hypercholesterolaemia
The Addition of Ezetimibe to Statin therapy in Patients with Homozygous Familial Hypercholesterolaemia Submitted in fulfilment with the requirements for the degree Master in Medicine (MMed) Dr Adriano
More informationLIPOPROTEINE ATEROGENE E ANTI-ATEROGENE ATEROGENE
LIPOPROTEINE ATEROGENE E ANTI-ATEROGENE ATEROGENE Sebastiano Calandra Dipartimento di Scienze Biomediche Università di Modena e Reggio Emilia Incidence Rate/1000 200-150 - 100-50 - Women 0 Men
More informationThe new england journal of medicine
The new england journal of medicine brief report Targeting in the Familial Chylomicronemia Syndrome Daniel Gaudet, M.D., Ph.D., Diane Brisson, Ph.D., Karine Tremblay, Ph.D., Veronica J. Alexander, Ph.D.,
More informationLipid metabolism in familial hypercholesterolemia
Lipid metabolism in familial hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationRole of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD
Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Our laboratory focuses on the role of apolipoprotein (apo) B- containing lipoproteins in normal
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition
More informationCHAPTER FORTY FIVE ENDOGENOUS LIPID TRANSPORT PATHWAY: VLDL AND IDL
CHAPTER FORTY FIVE ENDOGENOUS LIPID TRANSPORT PATHWAY: VLDL AND IDL You will notice that the endogenous pathway is very similar to the exogenous pathway What is the average daily amount of triacylglycerol
More informationMetabolism and Atherogenic Properties of LDL
Metabolism and Atherogenic Properties of LDL Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy & Affiliate Associate Professor of Internal
More informationHDL : A Treatment Target? ESC Paris M. John Chapman Ph.D., D.Sc., FESC. President, European Atherosclerosis Society
ESC Paris 2011 HDL : A Treatment Target? M. John Chapman Ph.D., D.Sc., FESC Director, Dyslipidemia and Atherosclerosis Research Unit, INSERM, University Pierre and Marie Curie, Hôpital de la Pitié-Salpetriere,
More informationIONIS-ANGPTL3-L, an antisense inhibitor to
IIS-AGPTL3-L Rx, an antisense inhibitor to angiopoietin-like protein 3 [AGPTL3] reduces plasma AGPTL3 and lipids in healthy volunteers with elevated triglycerides Teresa A. Brandt 1, Li-Jung Tai 1, Joseph
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in
More informationMonogenic causes of elevated HDL cholesterol and implications for development of new therapeutics
Clinical Lipidology ISSN: 1758-4299 (Print) 1758-4302 (Online) Journal homepage: http://www.tandfonline.com/loi/tlip20 Monogenic causes of elevated HDL cholesterol and implications for development of new
More informationClinical Track. Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Blood Pressure as Mediators From Obesity to Ischemic Heart Disease
Clinical Track Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Blood Pressure as Mediators From Obesity to Ischemic Heart Disease Anette Varbo, Marianne Benn, George Davey Smith, Nicholas
More informationHypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002
Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationRobert A. Vogel, MD Clinical Professor of Medicine University of Colorado Denver
Robert A. Vogel, MD Clinical Professor of Medicine University of Colorado Denver Disclosures: National Coordinator: ODYSSEY Outcomes Study (Phase III Sanofi) Speakers Bureau: Sanofi, Regeneron Case Report
More informationPPAR history of research
PPAR Rubens, 1640 PPAR history of research number of publications 3000 2000 1000 0 till now: : 16 296 publications 1985 1990 1995 2000 2005 year liver, brown adipocytes, kidney, heart, skeletal muscles,
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationLE IPERCHILOMICRONEMIE FAMILIARI
LE IPERCHILOMICRONEMIE FAMILIARI Livia Pisciotta Di.M.I.-Università di Genova HYPERCHYLOMICRONEMIA SYNDROME Ø Hypertriglyceridemia (>10 mmol/l, >877 mg/dl) Ø Fasting chylomicronemia Ø Recurrent abdominal
More informationLipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry
Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry Learning Objectives 1. Define lipoproteins and explain the rationale of their formation in blood. 2. List different
More informationHypertriglyceridemia and Cardiovascular Risk: A Cautionary Note About Metabolic Confounding
Hypertriglyceridemia and Cardiovascular Risk: A Cautionary Note About Metabolic Confounding Allan D. Sniderman 1*, Patrick Couture 2, Seth S. Martin 3, Jacqueline DeGraaf 4, Patrick R. Lawler 5, William
More informationAntisense and Antibodies as Game changers in refractory dyslipidemia. Erik Stroes AMC
Antisense and Antibodies as Game changers in refractory dyslipidemia Erik Stroes AMC Asymptomatic phase Plaque rupture There is a significant residual CVD risk at least partially modifiable Postponement
More informationGenomic approach for drug target discovery and validation
Genomic approach for drug target discovery and validation Hong-Hee Won, Ph.D. SAIHST, SKKU wonhh@skku.edu Well-known example of genetic findings triggering drug development Genetics Mendelian randomisation
More informationLipids and cardiovascular disease 3 Triglycerides and cardiovascular disease
Lipids and cardiovascular disease Triglycerides and cardiovascular disease Børge G Nordestgaard, Anette Varbo Lancet ; 8: 66 6 This is the third in a Series of three papers about lipids and cardiovascular
More informationANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism
ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism I. Chylomicrons (exogenous pathway) A. 83% triacylglycerol, 2% protein, 8% cholesterol plus cholesterol esters, 7% phospholipid (esp. phosphatidylcholine)
More informationAntisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
The new england journal of medicine Original Article Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia Daniel Gaudet, M.D., Ph.D., Veronica J. Alexander, Ph.D., Brenda
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationNovel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane
Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane Kostner, 2007 2008 LDL Target depends on your level of Risk Acute Plaque Rupture ACS (UA/NSTEMI/STEMI)
More informationNon-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017
Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Historical Basis for Fasting Lipids The initial classifications of hyperlipidemia proposed in 1967 were genetic and required
More informationPCSK9 R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
Journal of the American College of Cardiology Vol. 55, No. 25, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.02.044
More informationGenetics of Arterial and Venous Thrombosis: Clinical Aspects and a Look to the Future
Genetics of Arterial and Venous Thrombosis: Clinical Aspects and a Look to the Future Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center for Cardiovascular
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationTreatment of Atherosclerosis in 2007
Treatment of Atherosclerosis in 2007 Szilard Voros, M.D. Medical Director Cardiovascular MR and CT Piedmont Hospital, Piedmont Hospital Our Paradigm Genotype Phenotype Environment Atherosclerotic Disease
More informationCETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia
CETP inhibition: pros and cons Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies or membership of advisory boards from:
More informationBeyond LDL-Cholesterol
Biomarkers for Risk Stratification Beyond LDL-Cholesterol Athanasios J.Manolis Director Cardioilogy Dep, Asklepeion Hospital, Athens, Greece Adj. Professor of Medicine, Emory University Atlanta, USA Adj.
More informationMETABOLISM of ADIPOSE TISSUE
METABOLISM of ADIPOSE TISSUE 2. LF UK Prof. Rudolf Poledne, PhD. TYPES OF ADIPOSE TISSUE brown adipose tissue subcutaneous adipose tissue visceral adipose tissue ADIPOSE TISSUE FUNCTIONS: thermal isolation
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationFAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)
FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) Dr. Joseph L. Witztum Distinguished Professor of Medicine, Department of Medicine & Director, Atherosclerosis Research Group, University of California, San Diego
More informationProf. John Chapman, MD, PhD, DSc
Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris
More informationA Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease.
A Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease. Brian A. Ference MD, MPhil, MSc, John J. P. Kastelein
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationPlasma lipoproteins & atherosclerosis by. Prof.Dr. Maha M. Sallam
Biochemistry Department Plasma lipoproteins & atherosclerosis by Prof.Dr. Maha M. Sallam 1 1. Recognize structures,types and role of lipoproteins in blood (Chylomicrons, VLDL, LDL and HDL). 2. Explain
More informationUSING NON -TRADITIONAL RISK MARKERS IN ASSESSING CV RISK
USING NON -TRADITIONAL RISK MARKERS IN ASSESSING CV RISK JAMES M FALKO MD PROFESSOR OF MEDICINE UNIVERSITY OF COLORADO Adapted from: Rader D. N Engl J Med. 2000 hs-crp (mg/l) 6 5 4 3 2 1 *p
More informationIschemic heart disease (IHD) is the most common cause of
Common Cholesteryl Ester Transfer Protein Mutations, Decreased HDL Cholesterol, and Possible Decreased Risk of Ischemic Heart Disease The Copenhagen City Heart Study Birgit Agerholm-Larsen, MSc, PhD; Anne
More informationChapter VIII: Dr. Sameh Sarray Hlaoui
Chapter VIII: Dr. Sameh Sarray Hlaoui Lipoproteins a Lipids are insoluble in plasma. In order to be transported they are combined with specific proteins to form lipoproteins: Clusters of proteins and lipids.
More informationLipoprotein (a) Disclosures 2/20/2013. Lipoprotein (a): Should We Measure? Should We Treat? Health Diagnostic Laboratory, Inc. No other disclosures
Lipoprotein (a): Should We Measure? Should We Treat? Joseph P. McConnell, Ph.D. DABCC Health Diagnostic Laboratory Inc. Baptist Health South Florida Eleventh Annual Cardiovascular Disease Prevention International
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationT h e n e w e ngl a nd j o u r na l o f m e dic i n e
T h e n e w e ngl a nd j o u r na l o f m e dic i n e brief report Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia Kiran Musunuru, M.D., Ph.D., M.P.H., James P. Pirruccello, B.S.,
More informationChild born in year /3 will die before parents in US (diabetes)
Child born in year 2000-1/3 will die before parents in US (diabetes) ATP III identified 6 components of the metabolic syndrome that relate to CVD 1. Abdominal obesity 2. Atherogenic dyslipidemia (elevated
More informationDr G R Letchuman. Clogged by Cholesterol
Dr G R Letchuman Clogged by Cholesterol Main message Cholesterol management is all about reducing risk of CV events vs the side effects, hassle and cost of drugs News that it is no longer important to
More informationMUTATIONS IN THE APOLIPOPROTEIN B GENE, HYPERCHOLESTEROLEMIA, AND THE RISK OF ISCHEMIC HEART DISEASE
MUTATIONS IN THE APOLIPOPROTEIN B GENE, HYPERCHOLESTEROLEMIA, AND THE RISK OF ISCHEMIC HEART DISEASE ASSOCIATION OF MUTATIONS IN THE APOLIPOPROTEIN B GENE WITH HYPERCHOLESTEROLEMIA AND THE RISK OF ISCHEMIC
More informationraised triglycerides and residual cardiovascular risk
EARN 3 FREE CPD POINTS cardiovascular Leader in digital CPD for Southern African healthcare professionals Prof Dirk Blom University of Cape Town Heart Centre and Lipid Clinic Groote Schuur Hospital raised
More informationLipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers. New and Old Biomarkers. Disclosures
Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers William Cromwell, MD, FAHA, FNLA Diplomate, American Board of Clinical Lipidology Chief Lipoprotein and Metabolic
More informationThe Target is LDL, HDL not so much
The Target is LDL, HDL not so much HDL: A riddle wrapped in a mystery inside an enigma Jacques Genest MD Cardiovascular Research Laboratories McGill University Health Center Disclosure J. Genest MD 2013
More informationUnit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins
Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins - Cholesterol: It is a sterol which is found in all eukaryotic cells and contains an oxygen (as a hydroxyl group OH) on Carbon number
More informationCardiovascular Disease Prevention: Current Knowledge, Future Directions
Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal
More information行政院國家科學委員會補助專題研究計畫成果報告
NSC892314B002270 898 1 907 31 9010 23 1 Molecular Study of Type III Hyperlipoproteinemia in Taiwan β β ε E Abstract β Type III hyperlipoproteinemia (type III HLP; familial dysbetalipoproteinemia ) is a
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationLipoprotein Pathophysiology. Lipoprotein Pathophysiology
Lipoprotein Pathophysiology Genetic Dyslipidemia Thomas A. Hughes, M.D. Professor of Medicine Division of Endocrinology, Metabolism, and Diabetes University of Tennessee Health Science Center GW is a 47
More informationInflammation: Novel Target for Cardiovascular Risk Reduction
Inflammation: Novel Target for Cardiovascular Risk Reduction Andrew Zalewski, M.D. Thomas Jefferson University, Philadelphia GlaxoSmithKline, Philadelphia Why inflammation? Population-based studies: low
More informationIdentification and management of familial hypercholesterolaemia (FH) - An overview
Identification and management of familial hypercholesterolaemia (FH) - An overview National Collaborating Centre for Primary Care and Royal College of General Practitioners NICE Guideline CG 71 (August
More informationFamilial Hypercholeterolaemia
Familial Hypercholeterolaemia Is it all about statins? Gerald F Watts DSc PhD MD FRACP FRCP Professor and Head, Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital School of Medicine,
More informationSupplementary Online Content
Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationDyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More information